CytoMed Therapeutics Ltd (NASDAQ:GDTC) has a beta value of -0.82 and has seen 10.12 million shares traded in the recent trading session. The company, currently valued at $36.28M, closed the recent trade at $3.19 per share which meant it lost -$0.26 on the day or -7.54% during that session. The GDTC stock price is -52.35% off its 52-week high price of $4.86 and 62.38% above the 52-week low of $1.20. If we look at the company’s 10-day average daily trading volume, we find that it stood at 30580.0 shares traded. The 3-month trading volume is 23.23K shares.

CytoMed Therapeutics Ltd (NASDAQ:GDTC) trade information

Sporting -7.54% in the red today, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the GDTC stock price touched $3.19 or saw a rise of 21.23%. Year-to-date, CytoMed Therapeutics Ltd shares have moved -6.18%, while the 5-day performance has seen it change 10.38%. Over the past 30 days, the shares of CytoMed Therapeutics Ltd (NASDAQ:GDTC) have changed 0.31%. Short interest in the company has seen 62689.0 shares shorted with days to cover at 2.73.

CytoMed Therapeutics Ltd (GDTC) estimates and forecasts

The company’s shares have gained 59.50% over the past 6 months. 1 analysts offering their estimates for the company have set an average revenue estimate of 156k for the current quarter. 1 have an estimated revenue figure of 156k for the next ending quarter.

GDTC Dividends

CytoMed Therapeutics Ltd is expected to release its next earnings report in February this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.